Laxxon Medical Corp.

Laxxon Medical was founded in 2017. We hold the exclusive worldwide rights to the patented use and application of 3D screen printing technology for the development, manufacture and commercialization of pharmaceutical dosage forms.

With our innovative SPID®-Technology (Screen Printing Innovational Drug Technology), it is possible for the first time to develop oral, transdermal and implantable dosage forms through geometric shaping and heterogeneous distribution of active ingredients within the printed units yielding dosage forms with tailored release of active ingredients.

Our goal is to establish SPID®-Technology as a manufacturing process that has the individual and the industrial partner in mind. SPID®-Technology revolutionizes the pharmaceutical experience for the individual because of its ability to target the release of active ingredients in the tablet. For contractual partners, SPID®-Technology provides extended protection through technology transfer for existing and future products with the extensive IP of Laxxon Medical.